USA - NASDAQ:PMCB - US71715X2036 - Common Stock
The current stock price of PMCB is 0.96 USD. In the past month the price decreased by -10.28%. In the past year, price decreased by -46.67%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.59 | 403.98B | ||
AMGN | AMGEN INC | 13.57 | 159.34B | ||
GILD | GILEAD SCIENCES INC | 15.69 | 150.71B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 25.17 | 109.33B | ||
REGN | REGENERON PHARMACEUTICALS | 12.81 | 61.98B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.94B | ||
ARGX | ARGENX SE - ADR | 88.4 | 50.13B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.07 | 34.44B | ||
INSM | INSMED INC | N/A | 33.90B | ||
NTRA | NATERA INC | N/A | 25.81B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.54B | ||
BIIB | BIOGEN INC | 9.23 | 21.66B |
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
PHARMACYTE BIOTECH INC
3960 Howard Hughes Parkway, Suite 500
Las Vegas NEVADA US
CEO: Kenneth L. Waggoner
Employees: 2
Phone: 19175952850
The current stock price of PMCB is 0.96 USD. The price decreased by -1.88% in the last trading session.
The exchange symbol of PHARMACYTE BIOTECH INC is PMCB and it is listed on the Nasdaq exchange.
PMCB stock is listed on the Nasdaq exchange.
PHARMACYTE BIOTECH INC (PMCB) has a market capitalization of 45.25M USD. This makes PMCB a Nano Cap stock.
PHARMACYTE BIOTECH INC (PMCB) currently has 2 employees.
PHARMACYTE BIOTECH INC (PMCB) has a support level at 0.83 and a resistance level at 0.98. Check the full technical report for a detailed analysis of PMCB support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PMCB does not pay a dividend.
PHARMACYTE BIOTECH INC (PMCB) will report earnings on 2025-12-11.
PHARMACYTE BIOTECH INC (PMCB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.48).
The outstanding short interest for PHARMACYTE BIOTECH INC (PMCB) is 3.65% of its float. Check the ownership tab for more information on the PMCB short interest.
ChartMill assigns a technical rating of 1 / 10 to PMCB. When comparing the yearly performance of all stocks, PMCB is a bad performer in the overall market: 89.12% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to PMCB. PMCB has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months PMCB reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS decreased by -152.25% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -7.8% | ||
ROE | -8.07% | ||
Debt/Equity | 0 |